Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection.
about
Targeting TNF and TNF Receptor Pathway in HIV-1 Infection: from Immune Activation to Viral ReservoirsPreventing infective complications in inflammatory bowel disease.Is There a Potential Role for Anti-tumor Necrosis Factor Therapy in Patients with Human Immunodeficiency Virus?Efficacy of tumour necrosis factor-α antagonists in aphthous ulceration: review of published individual patient data.Carla Task Force on Sarcopenia: propositions for clinical trialsHepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategiesThe safety of etanercept for the treatment of plaque psoriasis.TNFα Impairs Rhabdoviral Clearance by Inhibiting the Host Autophagic Antiviral Response.A fatal case of hepatitis B virus (HBV) reactivation during long-term, very-low-dose steroid treatment in an inactive HBV carrier.Treatment of chronic inflammatory diseases with biologic agents: opportunities and risks for the elderly.Long-term safety of anti-TNF adalimumab in HBc antibody-positive psoriatic arthritis patients: a retrospective case series of 8 patientsEtanercept: long-term clinical experience in rheumatoid arthritis and other arthritis.The use of TNF-alpha blocking agents in rheumatoid arthritis: an update.Safety of cyclosporin A in HCV-infected patients: experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection.Invited commentary on David Fedson's articleRheumatic conditions in human immunodeficiency virus infection.Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectivesSarcopenia in women with rheumatoid arthritis.Soybean-derived Bowman-Birk Inhibitor (BBI) Inhibits HIV Replication in MacrophagesUse of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients.TNF and TNF receptor superfamily members in HIV infection: new cellular targets for therapy?Use of infliximab in particular clinical settings: management based on current evidence.A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review.Biological therapies for inflammatory bowel disease: controversies and future options.Biologics in oral medicine: principles of use and practical considerations.Management of rheumatic disease with comorbid HBV or HCV infection.The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease.Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxisHepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy.Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.Resistance to vaccinia virus is less dependent on TNF under conditions of heterologous immunity.Hepatitis C virus treatment complicated by rheumatoid arthritis.Exploring interaction of TNF and orthopoxviral CrmB protein by surface plasmon resonance and free energy calculation.The use of ustekinumab in a patient with severe psoriasis and positive HBV serology.Etanercept therapy in patients with psoriasis and concomitant HCV infection.Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases.Use of biological disease-modifying anti-rheumatic drugs in patients with concurrent rheumatic disease and hepatitis B.[Secondary immunodeficiency in rheumatological diseases].Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs.
P2860
Q33613493-12274E67-E5B0-4442-BDC0-1AEC7EACB319Q34008766-1D77D16B-50D0-4C92-A5B2-8CBC3B812F60Q34074149-265DC3BA-95F8-47B0-B084-7C078F76574BQ34142185-72E70C6F-F7B9-416B-A7C2-E241E695CCB4Q35031618-8DD4ED02-EB69-4FCD-9BD4-B5DE2FDD7C04Q35637506-F075DDD1-120F-445A-878C-C44E08CC77A4Q35919214-498CC7BB-3AD9-4772-B5AB-D65BC1816C06Q36063179-A2882D08-0A5D-40E1-B13C-CD51EE3DA3DEQ36154001-965B7AED-80D5-4890-AF98-676BA8D3CF92Q36663141-A7BF58FD-3FB3-493E-B51F-AA43F8DF7D22Q36757744-3D5D1CB0-4E75-466A-8B5D-7114A68AA889Q36847326-2606D63D-2E7A-477F-AB94-1D88F0723550Q36916918-2AA2175D-9058-4C8E-8093-958E6755C903Q36958375-1367D998-FF0F-4362-AF5F-0DE6DF4F1086Q37086826-54F1B953-0911-4BE7-8984-91D6B2E8D37BQ37138780-AABBD438-2B2A-42C7-80FD-2EC4B9E02CBBQ37211844-F31CE01B-9FCC-4E14-B553-EB575958F3CEQ37305184-69E4B7FA-DD60-40BD-BA3C-3C0300C9E6DBQ37335524-B231C623-F462-4FC7-B181-510F3700E3EFQ37416404-8CBBD290-93B7-4036-AA1E-ED3CD7E46A86Q37433321-BE690970-413E-4FF4-A39C-35BCF9DE7BB5Q37506064-F4C15F9A-40DB-41BF-A8D1-46AE1F036B14Q37814549-78C79C02-32D6-4665-97F3-524543D07155Q37892162-F456F959-C164-404E-BF43-E7A47B72A6ACQ37960183-486BF78B-543E-4B08-8006-21567B460CD2Q37993932-D6A9BCAA-3384-4CCD-9257-BD8F937714ADQ38008173-EA4B661E-6CCB-48CF-829A-C84B6BE06772Q38062336-B13FF723-7918-4640-8FA3-BBC2DEBB61C1Q38094015-0F88C06F-D8DE-4778-AE53-D8B72FA749ECQ38408897-EAD0D2F9-DE61-403C-AC1F-F5FF20CDDDA2Q38993250-871EAB9E-D2D0-4403-B4C8-C4B9E7331657Q39914179-2956D716-F345-4875-BDF3-7642532F1B1CQ40622385-A0ADB4A1-AF53-41C6-B00C-4816FAF67A66Q41142790-6DD100B6-6BEE-40AE-B5D9-D6065F8D898CQ42204345-B92689C5-F496-462B-B4B8-F59D7CE41B70Q42860236-F20289A0-D3DE-4ED7-B59B-8AA92AD70DF3Q43035871-5CAC99C9-B87B-4093-B158-7FE0F94E14ADQ44464843-79F08E9B-2E38-452B-B470-E7F964452511Q44975901-A87E6604-4A20-45C3-8ECA-10AF9136B119Q46162379-0F548D09-B2BE-4D85-BD82-96634D395D83
P2860
Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Safety of antitumour necrosis ...... epatitis B, and HIV infection.
@ast
Safety of antitumour necrosis ...... epatitis B, and HIV infection.
@en
type
label
Safety of antitumour necrosis ...... epatitis B, and HIV infection.
@ast
Safety of antitumour necrosis ...... epatitis B, and HIV infection.
@en
prefLabel
Safety of antitumour necrosis ...... epatitis B, and HIV infection.
@ast
Safety of antitumour necrosis ...... epatitis B, and HIV infection.
@en
P2860
P356
P1476
Safety of antitumour necrosis ...... hepatitis B, and HIV infection
@en
P2093
P2860
P304
P356
10.1136/ARD.2004.028209
P407
P478
63 Suppl 2
P577
2004-11-01T00:00:00Z